- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:59 | TETRATHERIX LIMITED: Becoming a substantial holder | - | ASX | ||
| 03:54 | TETRATHERIX LIMITED: Becoming a substantial holder | - | ASX | ||
| 03:52 | TETRATHERIX LIMITED: Becoming a substantial holder | - | ASX | ||
| 03:49 | TETRATHERIX LIMITED: Becoming a substantial holder | - | ASX | ||
| 01:26 | TETRATHERIX LIMITED: Investor Presentation | - | ASX | ||
| Mo | Health Check: Tetratherix breaks biotech IPO drought with 13pc gain on debut | 1 | Stockhead | ||
| Mo | TETRATHERIX LIMITED: Tetratherix lists on ASX following successful IPO | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Pre-Quotation Disclosure with various confirmations | - | ASX | ||
| TETRATHERIX Aktie jetzt für 0€ handeln | |||||
| Fr | TETRATHERIX LIMITED: Top 20 Holders | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Distribution Schedule | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Share Trading Policy | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Corporate Governance Statement | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Interim Financial Report - 31 December 2024 | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Annual Report 2023 and 2024 | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Constitution | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Supplementary Prospectus | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Prospectus | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Information Form and Checklist | - | ASX | ||
| Fr | TETRATHERIX LIMITED: Appendix 1A | - | ASX | ||
| Fr | TETRATHERIX LIMITED: ASX Market Announcement - Admission and Quotation | - | ASX |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,280 | +0,97 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,200 | -0,24 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 47,005 | 0,00 % | Merck schließt Übernahme von Springworks Therapeutics ab | DJ Merck schließt Übernahme von Springworks Therapeutics ab
DOW JONES--Der Pharma- und Technologiekonzern Merck hat die im April angekündigte Übernahme des US-Krebsspezialisten Springworks Therapeutics... ► Artikel lesen | |
| NUVALENT | 78,01 | +2,16 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| CG ONCOLOGY | 26,350 | +1,31 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,280 | +0,36 % | BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside | ||
| EVOTEC | 7,250 | +0,64 % | EQS-News: Evotec SE: Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis von akutem Nierenversagen | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 28,460 | +0,25 % | Expert Outlook: Avidity Biosciences Through The Eyes Of 11 Analysts | ||
| DYNE THERAPEUTICS | 8,655 | -9,13 % | Dyne Therapeutics Prices Public Offering Of About 24.24 Mln Shares At $8.25/shr | WASHINGTON (dpa-AFX) - Dyne Therapeutics Inc. (DYN) announced the pricing of an underwritten public offering of about 24.24 million shares of its common stock at a public offering price of $8.25... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,130 | +1,58 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| VERA THERAPEUTICS | 23,000 | -2,38 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| BIONTECH | 91,30 | +0,88 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
| TREVI THERAPEUTICS | 5,700 | +4,40 % | Cantor Fitzgerald initiates coverage on Trevi Therapeutics stock with Overweight rating | ||
| EDGEWISE THERAPEUTICS | 12,820 | -2,14 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| ARVINAS | 7,630 | +3,32 % | ARVINAS, INC. - 8-K, Current Report |
Das Unternehmen TETRATHERIX LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TETRATHERIX LIMITED finden Sie auf Wallstreet Online.